The Medical Letter on Drugs and Therapeutics
Drugs for Alcohol Use Disorder
December 13, 2021 (Issue: 1639)Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11...more
- BF Grant et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72:757.
- K Witkiewitz et al. Advances in the science and treatment of alcohol use disorder. Sci Adv 2019; 5:eaax4043.
- VI Reus et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry 2018; 175:86.
- U.S. Department of Veterans Affairs. VA/DoD clinical practice guideline for the management of substance use disorders. Version 4.0 – 2021. Available at: https://bit.ly/3CkSSEp. Accessed November 18, 2021.
- HR Kranzler and M Soyka. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA 2018; 320:815.
- Naltrexone for alcohol dependence. Med Lett Drugs Ther 1995; 37:64.
- Naltrexone (Vivitrol) – a once monthly injection for alcoholism. Med Lett Drugs Ther 2006; 48:62.
- Drugs for opioid use disorder. Med Lett Drugs Ther 2017; 59:89.
- S Rösner et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12:CD001867.
- RF Anton et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003.
- JR Volpicelli et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876.
- JR Volpicelli et al. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 1995; 152:613.
- JC Garbutt et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293:1617.
- Drug Interactions from The Medical Letter. Available at: www.medicalletter.org/subDIO.
- GP Overman et al. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacother 2003; 37:1090.
- BJ Mason and P Lehert. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012; 36:497.
- DE Jonas et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311:1889.
- MD Skinner et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 2014; 9: e87366.
- JC Blodgett et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 2014; 38:1481.
- G Martinotti et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol 2014; 34:709.
- A Manhapra et al. Topiramate pharmacotherapy for alcohol use disorder and other addictions: a narrative review. J Addict Med 2019; 13:7.
- BJ Mason et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2014; 174:70.
- RF Anton et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med 2020; 180:728.
- DE Falk et al. Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety. Alcohol Clin Exp Res 2019; 43:158.
- EM Laska et al. Gabapentin encarbil extended-release versus placebo: a likely responder reanalysis of a randomized clinical trial. Alcohol Clin Exp Res 2020; 44:1875.
- JC Garbutt et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology 2021; 46:2250.
- S Minozzi et al. Baclofen for alcohol use disorder. Cochrane Database Syst Rev 2018; 11:CD012557.
- C Chaignot et al. Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf 2018; 27:1239.
- TL Simpson et al. Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry 2018; 175:1216.
- SS O’Malley et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry 2018; 75:129.
- HM Pettinati et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167:668.
- HR Kranzler et al. Post-treatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res 2014; 38:3017.
- E Kelty et al. Prevalence and safety of acamprosate use in pregnant alcohol-dependent women in New South Wales, Australia. Addiction 2019; 114:206.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.